aTyr Pharma Sets October 16 Vote on 1-for-10 to 1-for-50 Reverse Split to Regain Nasdaq Compliance
ATYR is trading near its 52-week low of $0.395 (8.8% above the low).
Summary
aTyr Pharma's definitive proxy sets an October 16 special meeting to vote on a reverse stock split between 1-for-10 and 1-for-50, aimed at regaining Nasdaq's $1.00 minimum bid price before the November 30 compliance deadline.
Key Events · Corporate Governance and Compliance · ATYR
-
Reverse Split Vote Set for October 16
Shareholders will vote on a reverse stock split at a ratio between 1-for-10 and 1-for-50, with the board choosing the final ratio at its discretion.
-
Nasdaq Compliance Deadline November 30
The company received a deficiency notice in December 2025 for trading below $1.00 and was granted a second 180-day compliance period ending November 30, 2026.
-
Share Count Would Shrink Dramatically
At the maximum 1-for-50 ratio, outstanding shares would fall from 98,087,425 to 1,961,749, while authorized shares remain at 340 million, freeing up over 337 million shares for future issuance.
-
Delisting Risk if Split Fails
If the split is not approved or does not lift the stock above $1.00, Nasdaq could delist the stock, pushing it to less liquid OTC markets.
Analysis · ATYR · Life Sciences
aTyr Pharma is asking shareholders to approve a reverse stock split at a ratio between 1-for-10 and 1-for-50, with the board retaining discretion to pick the exact ratio. The company's stock has traded below Nasdaq's $1.00 minimum bid price since late 2025, and the exchange has given it until November 30, 2026 to regain compliance. Without the split, delisting to the OTC market is likely, which would reduce liquidity and institutional interest. The split itself does not change any shareholder's percentage ownership, but it would shrink the float from roughly 98 million shares to as few as 1.96 million, potentially increasing volatility. The board has also flagged that the split would effectively free up authorized shares for future financing, which could be dilutive down the road.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATYR was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.2M. The 52-week trading range was $0.40 to $6.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.